These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 7514683)

  • 1. Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies.
    Laal S; Burda S; Gorny MK; Karwowska S; Buchbinder A; Zolla-Pazner S
    J Virol; 1994 Jun; 68(6):4001-8. PubMed ID: 7514683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.
    Nyambi PN; Mbah HA; Burda S; Williams C; Gorny MK; Nádas A; Zolla-Pazner S
    J Virol; 2000 Aug; 74(15):7096-107. PubMed ID: 10888650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6.
    Verrier F; Nádas A; Gorny MK; Zolla-Pazner S
    J Virol; 2001 Oct; 75(19):9177-86. PubMed ID: 11533181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site.
    Vijh-Warrier S; Pinter A; Honnen WJ; Tilley SA
    J Virol; 1996 Jul; 70(7):4466-73. PubMed ID: 8676471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.
    Richardson TM; Stryjewski BL; Broder CC; Hoxie JA; Mascola JR; Earl PL; Doms RW
    J Virol; 1996 Feb; 70(2):753-62. PubMed ID: 8551612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1.
    Nyambi PN; Gorny MK; Bastiani L; van der Groen G; Williams C; Zolla-Pazner S
    J Virol; 1998 Nov; 72(11):9384-91. PubMed ID: 9765494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.
    McCaffrey RA; Saunders C; Hensel M; Stamatatos L
    J Virol; 2004 Apr; 78(7):3279-95. PubMed ID: 15016849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccine.
    Planque SA; Mitsuda Y; Nishiyama Y; Karle S; Boivin S; Salas M; Morris MK; Hara M; Liao G; Massey RJ; Hanson CV; Paul S
    J Immunol; 2012 Dec; 189(11):5367-81. PubMed ID: 23089396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.
    Park EJ; Gorny MK; Zolla-Pazner S; Quinnan GV
    J Virol; 2000 May; 74(9):4183-91. PubMed ID: 10756031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.
    Binley JM; Wrin T; Korber B; Zwick MB; Wang M; Chappey C; Stiegler G; Kunert R; Zolla-Pazner S; Katinger H; Petropoulos CJ; Burton DR
    J Virol; 2004 Dec; 78(23):13232-52. PubMed ID: 15542675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41.
    Allaway GP; Ryder AM; Beaudry GA; Maddon PJ
    AIDS Res Hum Retroviruses; 1993 Jul; 9(7):581-7. PubMed ID: 8369162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.
    Gorny MK; Williams C; Volsky B; Revesz K; Cohen S; Polonis VR; Honnen WJ; Kayman SC; Krachmarov C; Pinter A; Zolla-Pazner S
    J Virol; 2002 Sep; 76(18):9035-45. PubMed ID: 12186887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.
    Kang CY; Hariharan K; Nara PL; Sodroski J; Moore JP
    J Virol; 1994 Sep; 68(9):5854-62. PubMed ID: 7520095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of human immunodeficiency virus type 1 gp120 presentation to CD4 T cells by antibodies specific for the CD4 binding domain of gp120.
    Hioe CE; Tuen M; Chien PC; Jones G; Ratto-Kim S; Norris PJ; Moretto WJ; Nixon DF; Gorny MK; Zolla-Pazner S
    J Virol; 2001 Nov; 75(22):10950-7. PubMed ID: 11602735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein.
    Thali M; Furman C; Wahren B; Posner M; Ho DD; Robinson J; Sodroski J
    J Acquir Immune Defic Syndr (1988); 1992; 5(6):591-9. PubMed ID: 1588493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
    Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
    Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner.
    Musich T; Li L; Liu L; Zolla-Pazner S; Robert-Guroff M; Gorny MK
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28122974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of human monoclonal antibodies selected with a hypervariable loop-deleted recombinant HIV-1(IIIB) gp120.
    Jeffs SA; Gorny MK; Williams C; Revesz K; Volsky B; Burda S; Wang XH; Bandres J; Zolla-Pazner S; Holmes H
    Immunol Lett; 2001 Dec; 79(3):209-13. PubMed ID: 11600200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes.
    Tanaka K; Kuwata T; Alam M; Kaplan G; Takahama S; Valdez KPR; Roitburd-Berman A; Gershoni JM; Matsushita S
    Retrovirology; 2017 Sep; 14(1):44. PubMed ID: 28938888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.